240 related articles for article (PubMed ID: 15843468)
1. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia.
Liu S; Brown TA; Zhou J; Xiao ZS; Awad H; Guilak F; Quarles LD
J Am Soc Nephrol; 2005 Jun; 16(6):1645-53. PubMed ID: 15843468
[TBL] [Abstract][Full Text] [Related]
2. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
3. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM.
Addison WN; Nakano Y; Loisel T; Crine P; McKee MD
J Bone Miner Res; 2008 Oct; 23(10):1638-49. PubMed ID: 18597632
[TBL] [Abstract][Full Text] [Related]
4. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.
Argiro L; Desbarats M; Glorieux FH; Ecarot B
Genomics; 2001 Jun; 74(3):342-51. PubMed ID: 11414762
[TBL] [Abstract][Full Text] [Related]
5. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic role of Fgf23 in Hyp mice.
Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD
Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303
[TBL] [Abstract][Full Text] [Related]
8. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.
Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS
Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525
[TBL] [Abstract][Full Text] [Related]
9. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
10. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MEPE cleavage by Phex.
Guo R; Rowe PS; Liu S; Simpson LG; Xiao ZS; Quarles LD
Biochem Biophys Res Commun; 2002 Sep; 297(1):38-45. PubMed ID: 12220505
[TBL] [Abstract][Full Text] [Related]
12. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Oct; 79():131-42. PubMed ID: 26051469
[TBL] [Abstract][Full Text] [Related]
13. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
14. Contributions of increased osteopontin and hypophosphatemia to dentoalveolar defects in osteomalacic Hyp mice.
Mohamed FF; Hoac B; Phanrungsuwan A; Tan MH; Giovani PA; Ghiba S; Murshed M; Foster BL; McKee MD
Bone; 2023 Nov; 176():116886. PubMed ID: 37634682
[TBL] [Abstract][Full Text] [Related]
15. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.
David V; Martin A; Hedge AM; Drezner MK; Rowe PS
Am J Physiol Renal Physiol; 2011 Mar; 300(3):F783-91. PubMed ID: 21177780
[TBL] [Abstract][Full Text] [Related]
16. Defective Mineralization in X-Linked Hypophosphatemia Dental Pulp Cell Cultures.
Coyac BR; Hoac B; Chafey P; Falgayrac G; Slimani L; Rowe PS; Penel G; Linglart A; McKee MD; Chaussain C; Bardet C
J Dent Res; 2018 Feb; 97(2):184-191. PubMed ID: 28880715
[TBL] [Abstract][Full Text] [Related]
17. A novel Phex mutation in a new mouse model of hypophosphatemic rickets.
Owen C; Chen F; Flenniken AM; Osborne LR; Ichikawa S; Adamson SL; Rossant J; Aubin JE
J Cell Biochem; 2012 Jul; 113(7):2432-41. PubMed ID: 22573557
[TBL] [Abstract][Full Text] [Related]
18. Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition.
Miao D; Bai X; Panda D; McKee M; Karaplis A; Goltzman D
Endocrinology; 2001 Feb; 142(2):926-39. PubMed ID: 11159866
[TBL] [Abstract][Full Text] [Related]
19. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia.
Barros NM; Hoac B; Neves RL; Addison WN; Assis DM; Murshed M; Carmona AK; McKee MD
J Bone Miner Res; 2013 Mar; 28(3):688-99. PubMed ID: 22991293
[TBL] [Abstract][Full Text] [Related]
20. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.
Bresler D; Bruder J; Mohnike K; Fraser WD; Rowe PS
J Endocrinol; 2004 Dec; 183(3):R1-9. PubMed ID: 15590969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]